Takeaways: This approval strengthens Lilly’s competitive stance against other GLP-1/GIP agents in the obesity space by adding a disease-specific indication (OSA) that ties directl...
Takeaways Hims & Hers is using generic semaglutide to anchor its Canadian weight‑loss and metabolic program, giving it a priced‑in, recurring revenue product at about CAD 149/month that...
Takeaways Phoenix and Raven are turning Canada’s new generic semaglutide approvals into immediate, retail-like access, which will likely accelerate GLP‑1 uptake beyond traditional bric...
Takeaways: Felix is positioning itself as the price‑breaker in Canada’s GLP‑1 obesity market, using cheaper semaglutide (as generics arrive) to tackle the main dropout driver and convert strong ...
The Obesity Drug Gold Rush: Healthcare Breakthrough or Market Frenzy? The global pharmaceutical industry is witnessing an unprecedented surge in demand for obesity therapies, transforming what was onc...
